Inhalable tobramycin EEG powder formulation for treating Pseudomonas aeruginosa-induced lung infection.

ABSTRACT: Pulmonary delivery of antibiotics is an effective strategy in treating bacterial lung infection for cystic fibrosis patients, by achieving high local drug concentrations and reducing overall systemic exposure compared to systemic administration. However, the inherent anatomical lung defense mechanisms, formulation characteristics, and drug-device combination determine the treatment efficacy of the aerosol delivery approach. In this study, we prepared a new tobramycin (Tobi) dry powder aerosol using excipient enhanced growth (EEG) technology and evaluated the in vitro and in vivo aerosol performance. We further established a Pseudomonas aeruginosa-induced lung infection rat model using an in-house designed novel liquid aerosolizer device. Notably, novel liquid aerosolizer yields comparable

SUBMITTER: Pangeni R 

PROVIDER: S-EPMC11344668 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature